FDA Authorizes IND For Phase 2 Clinical Trial Evaluating Treatment for Post–COVID-19 Condition
The FDA has authorized BioVie's investigational new drug application for bezisterim to treat neurological symptoms associated with post–COVID-19 condition. A phase 2 trial will evaluate bezisterim's safety, tolerability, and potential to reduce neurocognitive symptoms in 200 patients over 3 months. Bezisterim, which acts on inflammatory pathways, is also being investigated for Alzheimer Disease and Parkinson Disease.
Related Clinical Trials
Highlighted Terms
Related News
BioVie Inc's FDA-authorized phase 2 trial will evaluate bezisterim for long COVID, aiming to reduce neurocognitive symptoms. Bezisterim, an anti-inflammatory insulin sensitizer, also shows promise in Alzheimer and Parkinson diseases.
The FDA has authorized BioVie's investigational new drug application for bezisterim to treat neurological symptoms associated with post–COVID-19 condition. A phase 2 trial will evaluate bezisterim's safety, tolerability, and potential to reduce neurocognitive symptoms in 200 patients over 3 months. Bezisterim, which acts on inflammatory pathways, is also being investigated for Alzheimer Disease and Parkinson Disease.